Our look is new. Our purpose is the same. Learn more about our brand evolution.
From Arrowhead Pharmaceuticals PASADENA, Calif.–(BUSINESS WIRE)–Jul. 17, 2023– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial […]
Preliminary findings from our survey to understand the economic impact of FSHD by June Kinoshita, FSHD Society As a growing number of drugs enter clinical trials for FSHD, a question […]
Not every person with FSHD will need a mobility device, but many will at some point. The many designs and brands on the market can be daunting.
Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiative from Fulcrum Therapeutics Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics announce the launch of […]
